Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jackie Palace

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Journal of the Neurological Sciences|February 1, 2003
Clinical and laboratory characteristics of secondary progressive MSJackie Palace
Journal of Neuroimmunology|August 19, 2008
The congenital myasthenic syndromesJackie Palace, David Beeson
Expert Review of Neurotherapeutics|February 4, 2016
Therapeutic options in neuromyelitis optica spectrum disordersJoanna Kitley, Jackie Palace
Molecular & Cellular Proteomics : MCP|April 1, 2009
Immunocapture and identification of cell membrane protein antigenic targets of serum autoantibodiesEdward Littleton, Mathias Dreger, Jackie Palace, et al.
BMC Neurology|August 17, 2022
Systematic literature review and meta-analysis of the prevalence of secondary progressive multiple sclerosis in the USA, Europe, Canada, Australia, and BrazilVijayalakshmi Vasanthaprasad, Vivek Khurana, Sreelatha Vadapalle, et al.
Annals of the New York Academy of Sciences|June 10, 2003
Antibodies to neuronal targets in neurological and psychiatric diseasesAngela Vincent, Paola Dalton, Linda Clover, et al.
Autoimmunity|April 13, 2010
Clinical aspects of myasthenia explainedJan J G M Verschuuren, Jackie Palace, Nils Erik Gilhus
Magnetic Resonance in Medicine|October 31, 2007
Axonal damage in the spinal cord of multiple sclerosis patients detected by magnetic resonance spectroscopyAndrew M Blamire, Sarah Cader, Martin Lee, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 4, 2015
Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMOJoanna Kitley, Mark Woodhall, M Isabel Leite, et al.
Journal of the Neurological Sciences|March 1, 2014
Catastrophic brain relapse in seronegative NMO after a single dose of natalizumabJoanna Kitley, Nikos Evangelou, Wilhelm Küker, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Journal of the Neurological Sciences|February 1, 2003
Clinical and laboratory characteristics of secondary progressive MSJackie Palace
Journal of Neuroimmunology|August 19, 2008
The congenital myasthenic syndromesJackie Palace, David Beeson
Expert Review of Neurotherapeutics|February 4, 2016
Therapeutic options in neuromyelitis optica spectrum disordersJoanna Kitley, Jackie Palace
Molecular & Cellular Proteomics : MCP|April 1, 2009
Immunocapture and identification of cell membrane protein antigenic targets of serum autoantibodiesEdward Littleton, Mathias Dreger, Jackie Palace, et al.
BMC Neurology|August 17, 2022
Systematic literature review and meta-analysis of the prevalence of secondary progressive multiple sclerosis in the USA, Europe, Canada, Australia, and BrazilVijayalakshmi Vasanthaprasad, Vivek Khurana, Sreelatha Vadapalle, et al.
Annals of the New York Academy of Sciences|June 10, 2003
Antibodies to neuronal targets in neurological and psychiatric diseasesAngela Vincent, Paola Dalton, Linda Clover, et al.
Autoimmunity|April 13, 2010
Clinical aspects of myasthenia explainedJan J G M Verschuuren, Jackie Palace, Nils Erik Gilhus
Magnetic Resonance in Medicine|October 31, 2007
Axonal damage in the spinal cord of multiple sclerosis patients detected by magnetic resonance spectroscopyAndrew M Blamire, Sarah Cader, Martin Lee, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 4, 2015
Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMOJoanna Kitley, Mark Woodhall, M Isabel Leite, et al.
Journal of the Neurological Sciences|March 1, 2014
Catastrophic brain relapse in seronegative NMO after a single dose of natalizumabJoanna Kitley, Nikos Evangelou, Wilhelm Küker, et al.
Pageof 3